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Objectives: Management of liver metastasis (LM) from a non-colorectal, non-neuroendocrine primary
carcinoma remains controversial. Few data exist on the management of hepatic metastasis from primary
renal cell carcinoma (RCC). This study sought to determine the safety and efficacy of surgery for RCC LM.
Methods: A total of 43 patients who underwent surgery for RCC hepatic metastasis between 1994 and
2011 were identified in a multi-institution hepatobiliary database. Clinicopathologic, operative and
outcome data were collected and analysed.
Results: Mean patient age was 62.4 years and most patients (67.4%) were male. The mean tumour size
of the primary RCC was 6.9 cm and most tumours (72.1%) were designated as clear cell carcinoma. Nine
patients (20.9%) presented with synchronous LM. Among the patients with metachronous disease, the
median time from diagnosis of the primary RCC to treatment of LM was 17.2 months (range: 2.1–189.3
months). The mean size of the RCC LM was 4.0 cm and most patients (55.8%) had a solitary metastasis.
Most patients (86.0%) underwent a minor resection (up to three segments). Final pathology showed
margin status to be negative (R0) in 95.3% of patients. Postoperative morbidity was 23.3% and there was
one perioperative death. A total of 69.8% of patients received perioperative chemotherapy. Overall 3-year
survival was 62.1%. Three-year recurrence-free survival was 27.3% and the median length of recurrence-
free survival was 15.5 months.
Conclusions: Resection of RCC hepatic metastasis is safe and is associated with low morbidity and
near-zero mortality. Although recurrence occurs in up to 50% of patients, resection can be associated
with long-term survival in a well-selected subset of patients.
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Introduction
An estimated 58 000 Americans were diagnosed with renal cell
carcinoma (RCC) during 2010 and 13 000 died of this disease.1
Although many patients with RCC present with early-stage
disease, a subset of patients will develop metastatic disease. In
general, metastatic disease from RCC has been associated with a
poor prognosis, with 5-year survival ranging from 5% to 15%.1–6
Among patients with metastatic disease, resection represents the
only hope for cure, but indications for surgery of metastatic RCC
remain poorly defined. Patients with oligometastatic disease that
is restricted to one organ may be candidates for surgical therapy
and may derive a survival benefit.1
Most data on resection of metastatic RCC come from series
examining the role of surgery in RCC metastatic to the lung
because the lung is the most common site of RCC metastasis.5
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Although it is less common, the liver is another frequent site of
metastatic disease. Unfortunately, the development of hepatic
metastasis is generally considered a poor prognostic factor and is
often associated with more widespread disease. A subset of
patients, however, will have metastatic RCC confined to the liver
and surgical therapy may be warranted. Most data on the surgical
management of RCC hepatic metastasis are largely anecdotal or
derived from limited case reports.6,7 Although larger series that
focus on non-colorectal, non-neuroendocrine metastasis have
been published, patients with RCC metastasis represented only a
small subgroup in these samples and were not the focus of these
studies.8
The objective of this study was to assess the efficacy of surgical
therapy for hepatic metastasis of RCC in a large cohort of
patients treated at three major hepatobiliary centres. Specifically,
the study sought to define the benefit of surgery in a well-
selected group of patients with RCC liver metastasis (LM) and
to determine which factors were associated with prognosis. To
evaluate the relative survival benefit in patients operated for
RCC LM, the study utilized a matched-pair analysis to compare
outcomes in patients undergoing surgery for RCC LM with
outcomes in patients operated for colorectal carcinoma (CRC)
LM.
Materials and methods
Using an international, multi-institution database, 43 patients
with histologically proven RCC LM who underwent surgical
resection with curative intent between January 1994 and January
2011 at one of three institutions (Johns Hopkins University
School of Medicine, Baltimore, MD, USA; Ospedale San Raffaele,
Milan, Italy; Royal Prince Alfred Hospital, Sydney, NSW, Austra-
lia) were identified. The institutional review board of each insti-
tution approved this study. Only patients with histologically
confirmed RCC who were treated for RCC at a study centre were
included.
Data collection
Standard demographic and clinicopathologic data were collected,
including sex, age and primary tumour characteristics. Specifi-
cally, data were collected on primary tumour location and size, as
well as histologic subtype. Data on treatment-related variables,
such as type of surgery (complete or partial nephrectomy) and
adjuvant therapy, were also obtained. Similar data were collected
on the number, size and location of metastatic hepatic lesions, as
well as time to RCC LM (i.e. synchronous vs. metachronous). Data
on the utilization of perioperative chemotherapy were obtained.
Operative information included type of liver-directed therapy (i.e.
resection, ablation) and extent of resection. Hepatectomy was
classified as minor (less than three segments) or major (three or
more segments). Margin status was ascertained based on final
pathologic assessment. Data on operative morbidity and mortality
were recorded. The date of last follow-up and vital status were
collected for all patients.
Statistical analysis and matching cohort
Summary statistics were obtained using established methods and
presented as percentages, means or median values. Data were
analysed using Student’s t-test and Wilcoxon rank sum test for
continuous variables, and the chi-squared test or Fisher’s exact
test for discrete variables, where appropriate. Overall survival was
examined using the Kaplan–Meier method and compared using
the log-rank test. In order to compare subgroups of patients who
underwent surgery for hepatic metastasis of, respectively, RCC
and CRC, a 1 : 3 matched controlled analysis was performed. Spe-
cifically, patients were matched for age, date of surgery, disease-
free interval between primary and metastatic disease, and the size
and number of LM lesions, as well as for the presence of any
extrahepatic disease. Statistical analyses were performed using
stata Version 11.2 for Macintosh (StataCorp LP, College Station,
TX, USA).
Results
Patient, tumour and primary surgery characteristics
Characteristics of the 172 patients included in the current study
are detailed in Table 1. Of the 172 patients, 43 patients had RCC
metastatic to the liver and 129 had CRC hepatic metastasis and
served as the control cohort. Among the patients with RCC
hepatic metastasis, mean patient age was 62.4 years and most
patients (67.4%) were male. There was a relatively equal distribu-
tion of primary tumour location (right kidney, 46.5%; left kidney,
53.5%); the majority (83.8%) of patients had lymph node
metastasis associated with the primary tumour. The mean size of
the RCC primary tumour was 6.9 cm (range: 3.0–13.0 cm) and
most tumours were pathologic T3 lesions (T1, 34.9%; T2, 14.0%;
T3, 46.5%; T4, 4.6%). The most prevalent histology of the
primary kidney cancer showed clear cell carcinoma (72.1%), fol-
lowed by chromophobe carcinoma (18.6%).
Although nine (20.9%) patients presented with synchronous
RCC LM, the overwhelming majority (n = 34, 79.1%) developed
metachronous disease after a median disease-free interval of 17.2
months (range: 2.1–189.3 months). The majority of patients (n =
24, 55.8%) had a solitary hepatic metastasis. The median size of
the largest lesion was 4.0 cm (range: 2.0–15.0 cm). A subset of
patients had extrahepatic disease in conjunction with liver disease
(n = 14, 32.6%). Patients with RCC LM and those with CRC LM
were comparable regarding the clinicopathologic factors on which
they were matched (Table 1).
Of the 43 patients with RCC LM who underwent surgery, 30
(69.8%) patients received chemotherapy. Adjuvant chemotherapy
was administered to 25 (58.1%) patients and five patients received
neoadjuvant chemotherapy. Chemotherapy consisted of immu-
notherapy (n = 4), cytotoxic therapy (n = 21), or a combination of
both (n = 5).
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Table 1 Clinicopathologic characteristics of patients with renal cell carcinoma (RCC) liver metastasis (LM) and matched controls with
colorectal carcinoma (CRC) LM
RCC LM group (n = 43) CRC LM group (n = 129)
Age, years, mean (standard deviation) 62.4 (10.8) 61.5 (12.5)
Male sex, n (%) 29 (67.4) 84 (65.1)
Primary tumour
Size, cm, median (range) 6.9 (3–13) –
Right side, n (%) 20 (46.5) –
Histology, n (%)
Clear cell 31 (72.1) –
Chromophobe 8 (18.6) –
Papillary 4 (9.3) –
Grade, n (%)
Low (Fuhrman 1–2) 11 (25.6) –
High (Fuhrman 3–4) 32 (74.4) –
Caval tumour thrombus, n (%)
No 34 (79.1) –
Below the insertion of the hepatic veins 4 (9.3) –
Within the intrahepatic vena cava 5 (11.6) –
Intra-atrial tumour thrombus extension 0 –
Staging on presentation
T-stage, n (%)
T1 15 (34.9) –
T2 6 (14.0) –
T3 20 (46.5) –
T4 2 (4.6) –
N-stage, n (%) 43 (100) –
N0 7 (16.3) –
N1 30 (69.8) –
N2 6 (13.9) –
Hepatic metastasis
Size of the largest lesion, cm, median (range) 4.0 (2.0–15.0) 3.4 (0.5–11.0)
Number of hepatic metastases, n (%)
Solitary 24 (55.8) 72 (55.8)
2–5 19 (44.2) 57 (44.2)
Bilobar distribution, n (%) 6 (14.0) –
Liver-directed therapy
Disease-free interval >12 months, n (%) 21 (48.8) 68 (52.7)
Type of liver resection, n (%)
<3 segments 36 (85.7) 77 (59.7)
3 segments 6 (14.3) 52 (40.3)
Ablation, n (%) 7 (16.3) 10 (7.8)
Margin status, n (%)
R0 41 (95.3) 125 (96.9)
R1 2 (4.7) 4 (3.1)
Chemotherapy, n (%)
Adjuvant 25 (58.1) –
Neoadjuvant 5 (11.6) –
Cytotoxic 21 (48.8) –
Immunotherapy 4 (9.3) –
Both 5 (11.6) –
Extrahepatic metastases, n (%) 14 (32.6) 38 (29.5)
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Details of liver-directed surgery and
postoperative course
All patients with synchronous LM (n = 9) underwent an extended
procedure in which hepatic resection was carried out at the same
time as resection of the primary renal tumour; no patient under-
went staged liver-directed surgery. Overall, among the 43 patients
with RCC LM, surgery consisted of resection only (n = 36, 83.7%),
ablation only (n = 1, 2.3%) or combined resection and ablation
(n = 6, 14.0%). Among patients who underwent resection, the
extent of resection was minor in most patients (n = 36, 85.7%). On
final pathologic analysis of the liver specimen, the overwhelming
majority of patients (n = 41, 95.3%) had a negative hepatic margin
(R0); only two patients (4.7%) were noted to have microscopic
disease at the margin (R1) and no patient had residual macro-
scopic disease (R2).
There was one postoperative death within 30 days of surgery,
giving a mortality rate of 2.3%. Ten patients experienced a post-
operative complication, giving a morbidity rate of 23.3%. Most
complications (n = 7) were related to wound infection, bleeding
and respiratory insufficiency.
Recurrence and overall survival
Following liver-directed surgery, 18 (41.9%) patients suffered
recurrence after a median disease-free interval of 15.5 months
(range: 3.1–76.4 months) (Fig. 1). Among the 18 patients with
recurrence, the pattern of recurrence was intrahepatic only in 13
(30.2%) patients, extrahepatic only in three (7.0%) patients, and
both intra- and extrahepatic in two (4.7%) patients.
A matched analysis was performed to assess the impact of liver-
directed therapy for RCC hepatic metastasis compared with the
more traditional indication of CRC LM. Specifically, patients
who underwent surgery for LM of, respectively, RCC and CRC
were matched 1 : 3 for age, date of surgery, disease-free interval
between primary and metastatic disease, and size and number of
LM lesions, as well as for the presence of any extrahepatic disease.
Following liver-directed surgery, median disease-free survival was
found to be slightly worse in patients who underwent resection of
RCC LM (15.5 months) than in patients who underwent surgery
for CRC LM (26.9 months), but the difference was not statistically
significant (P = 0.142). Overall median survival in patients who
underwent surgery for RCC LM was not reached (range: 2.0–
109.1 months), whereas that in patients who underwent resection
of CRC LM was 62.9 months (range: 0.6–136.7 months) (P =
0.582) (Table 2). One- and 3-year survival rates in patients who
underwent liver-directed surgery for RCC LM (94.2% and 62.1%,
respectively) were comparable with those in patients operated for
CRC LM (89.4% and 69.2%, respectively) (P = 0.582) (Table 2,
Fig. 2).
On univariate analyses, disease-free interval and presence
of extrahepatic disease were associated with overall survival
(Table 3). Median survival after surgery for RCC LM in patients
who had a disease-free interval of 12 months between the time
of LM and primary tumour diagnosis was 21.5 months and was
thus worse than that in patients who had a disease-free interval of
>12 months (not reached) (P = 0.021). Similarly, median survival
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Figure 1 Following liver-directed surgery, 41.9% of patients oper-
ated for renal cell carcinoma (RCC) liver metastasis (LM) suffered
recurrence. Median disease-free survival was 15.5 months in
patients undergoing resection of RCC LM and 26.9 months in
patients operated for colorectal carcinoma LM (P = 0.142)
Table 2 Disease-free and overall survival in patients with renal cell carcinoma (RCC) liver metastasis (LM) and matched controls with
colorectal carcinoma LM
RCC LM group (n = 43) CRC LM group (n = 129) P-value
Disease-free survival, n (%)
1-year 79.5 (56.9–91.1) 82.8 (73.1–88.9)
3-year 27.3 (7.5–52.1) 33.3 (22.3–44.6)
Time to recurrence, months, median (range) 15.5 (3.1–76.4) 26.9 (3.4–32.8) 0.142
Overall survival, n (%)
1-year 94.2 (81.9–99.6) 89.4 (87.3–97.0)
3-year 62.1 (36.8–83.2) 69.2 (58.0–77.9)
Survival, months, median (range) NR (2.0–109.1) 62.9 (0.6–136.7) 0.582
NR, not reached.
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in patients with extrahepatic disease before or at liver surgery was
worse than in patients without extrahepatic disease (median sur-
vival: 21.9 months vs. not reached; P = 0.033) (Fig. 3).
Discussion
The management of patients with non-neuroendocrine, non-
colorectal LM has been a topic of increasing interest.8–10 Data from
these studies have largely focused on patients with metastasis
from breast cancer, sarcomas, melanomas and a variety of non-
colorectal gastrointestinal primary tumours. Patients with RCC
LM have not been a focus of these reports and data on this topic
remain scarce. As such, information on whether surgery plays a
role in outcomes in patients with RCC LM remains controversial.
Surgery for RCC LM is a particular subject of debate as RCC LM
has been thought to indicate a particularly poor prognosis com-
pared with RCC lung metastasis.5,6,11 The current study is impor-
tant because it examines outcomes in a relatively large cohort of
patients managed with surgery for RCC LM. Although these
patients were obviously highly selected, the data suggest that liver-
Table 3 Univariate analysis of prognostic factors for disease-free and overall survival
Median survival,
months
P-value Median time to
recurrence, months
P-value
Disease-free interval
12 months 21.5 14.8
>12 months NR 0.022 14.1 0.762
Number of lesions
One 39.9 19.9
Multiple lesions NR 0.761 14.1 0.711
Extrahepatic disease
No NR 14.8
Yes 21.9 0.024 14.1 0.663
Size of the largest lesion
5 cm NR 15.5
>5 cm 21.9 0.433 8.9 0.384
Grade
Low (Fuhrman 1–2) 21.4 15.4
High (Fuhrman 3–4) 46.5 0.913 19.9 0.052
NR, not reached.
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Figure 2 Overall median survival in patients who underwent liver-
directed surgery for renal cell carcinoma liver metastasis (LM) was
comparable with that in patients operated for colorectal carcinoma
LM (P = 0.582)
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Figure 3 In patients with renal cell carcinoma liver metastasis,
median survival was worse in those with extrahepatic disease than
in those without extrahepatic disease (median survival: 21.9 months
vs. not reached; P = 0.033)
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directed surgery in a subset of patients with RCC LM can be
associated with long-term survival. Data from the current study
show that surgery is safe, is associated with low rates of morbidity
and mortality and with 5-year survival of ª60%. In fact, overall
survival in patients operated for RCC LM was similar to that in a
matched cohort of patients who underwent surgery for CRC LM.
Taken together, these data suggest that a surgical approach to
hepatic metastasis from RCC is justified in a select subset of
patients.
Recently, Ruys and colleagues published their experience in the
surgical treatment of RCC LM.6 Their study reported on patients
retrieved from the local databases of the Netherlands Task Force
for Liver Surgery. The study included 33 patients who underwent
either resection (n = 29) or local ablation (n = 4) of RCC LM at
one of 14 centres. Although the current study is comparable with
that by Ruys et al.,6 the present series involved a larger number of
patients (n = 43) from dramatically fewer centres (n = 3). None-
theless, these data underscore the relative rarity and highly
selected nature of patients with RCC LM who are offered and
eventually undergo surgical therapy. In the current series, the
overwhelming majority of patients (79.1%) had metachronous
disease and most patients (55.8%) had a solitary hepatic metasta-
sis that measured <5 cm. Surgery was therefore offered only to a
very select subset of patients who had a low burden of disease that
often presented in a metachronous fashion. Although the current
study did not allow for the estimation of the overall utilization of
surgery in patients presenting with RCC LM, others have esti-
mated that fewer than 5% of patients with RCC LM are candidates
for surgical resection.6
It may be that the very stringent patient selection criteria
applied in the present study had some influence on the finding
that overall survival following surgery for RCC LM in this series
was very good. In fact, the present study reports a 5-year overall
survival following liver-directed surgery for RCC LM of ª60%.
This is somewhat superior to 5-year survival rates of 40–45%
reported in several other series.6–8,12 The reasons for this are prob-
ably multifactorial, but may relate, in part, to the population-
based nature of previous data.6 In particular, the study by Ruys
et al. represented a population-based experience from the Neth-
erlands and included patients from a large number of centres
without standardization of selection criteria or operative
approach.6 Previous studies have noted that population-based
data are often associated with worse short- and long-term out-
comes compared with institution-level data.13–15 The current study
not only used institution-level data, but also compared outcomes
in patients with RCC LM with those in an internal control group
by performing a 1 : 3 matched analysis of outcomes in RCC LM
patients matched with CRC LM patients on a number of clinico-
pathologic factors. On matched analysis, overall survival in
patients with RCC LM was comparable with that in patients with
CRC LM (Fig. 2). In sum, the findings on survival presented in the
current study and in previous studies suggest it is possible to
identify a subset of RCC LM patients in whom outcomes of
hepatic resection will be similar to those reported in CRC LM
patients.6–8,12
Two factors were associated with overall survival: disease-free
interval, and presence of extrahepatic disease (Fig. 3). Specifi-
cally, metachronous disease with a disease-free interval of 12
months was strongly associated with increased survival. Patients
with a disease-free interval of 12 months had a median sur-
vival that was not reached, whereas median survival in patients
with a disease-free interval of <12 months was only 21.5
months. Ruys et al. reported that patients with synchronous
disease had significantly worse survival compared with patients
who presented with metachronous LM.6 Staehler et al. similarly
noted that patients with metachronous disease had a median
survival of 155 months, whereas patients with synchronous
disease had a median survival of 29 months.16 The presence of
extrahepatic disease was also associated with long-term
outcome. Extrahepatic disease has been considered a relative
contraindication for liver resection in CRC LM and the presence
of extrahepatic disease has been shown to adversely impact sur-
vival following resection of CRC LM.17 Among RCC LM
patients, extrahepatic disease also adversely affected outcome as
these patients achieved a median survival of only 21.9 months
following liver resection. In RCC patients with LM, the present
data strongly suggest that patients with a long disease-free inter-
val and those with no extrahepatic disease derive the most
benefit from surgical therapy.
The present study has several limitations. Although the study
combined data from three major hepatobiliary centres, the overall
sample size was still somewhat small. As such, statistical analyses
were limited and causal inferences should be considered in this
light. Given that the study was retrospective in nature, like many
studies of surgical outcomes, it is undoubtedly affected by selec-
tion bias in how patients were chosen for surgical therapy. For
example, the use of preoperative chemotherapy may be an impor-
tant selection tool, but only five patients received neoadjuvant
therapy and thus this factor could not be more fully examined.
The aim of the current study, however, was to define whether
surgical resection was feasible and beneficial in a select subset of
patients with RCC LM.
In conclusion, the present study demonstrates that surgical
therapy for metastatic RCC to the liver is beneficial and results in
good long-term survival in a subset of patients. Patients undergo-
ing surgery for RCC LM achieved outcomes similar to those found
in a matched group of CRC LM patients. The low number of
patients with RCC LM who underwent surgical resection, and the
low burden of disease among these patients, underscore the very
selective nature of the current cohort. However, the present data
do suggest that surgical therapy should be considered in select
patients with RCC LM as a subset of patients can derive long-term
benefit.
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